The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

Published Date: 22 Apr 2024

Compared to chemotherapy, the ALK inhibitor lowered the risk of death or recurrence by 76%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says

2.

The response of bipolar patients to lithium may be predicted by ancestry.

3.

Daily physical activity, even at light intensities, linked to lower cancer risk

4.

How to keep your prostate healthy and lower your risk of developing serious problems

5.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot